AVNEET KAUR: Open Payments
NPI 1144704735 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$651 in 13 payments from 8 companies in 2025. Trend: 2023 $640 · 2024 $644 · 2025 $651
Food & beverage: $651
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $139 |
| Janssen Pharmaceuticals, Inc | 1 | $104 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $97 |
| Alexion Pharmaceuticals, Inc. | 1 | $94 |
| Novo Nordisk Inc | 4 | $83 |
| Lilly USA, LLC | 3 | $82 |
| Astellas Pharma US Inc | 1 | $34 |
| Esperion Therapeutics, Inc. | 1 | $18 |
Products named: INGREZZA, SPRAVATO, Wegovy, MOUNJARO, Veozah, ZEPBOUND, NEXLETOL.
Industry payments across MD — which companies pay providers there.
